COVID-19 vaccine in the world
The Sputnik V vaccine, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against coronavirus.
Sputnik V is based on a safe and tested human adenovirus vector platform. Using two different human adenoviral vectors is a unique approach that allows to boost the immune response and provide long lasting immunity.
The efficacy of the Sputnik V vaccine is confirmed at 91.6 %, the results of a Phase III clinical trial of the vaccine are published in the Lancet, one of the world’s oldest and most respected medical journals. According to analysis of data from 3.8 million vaccinated persons in Russia Sputnik V demonstrates 97.6 % efficacy. The vaccine provides 100 % protection against severe COVID-19.
RDIF jointly with partners and manufacturers is ramping up the production of Sputnik V. The lyophilized (dry) form of the vaccine can be stored at a temperature of +2 to +8 degrees Celsius, which allows for easy distribution worldwide, including hard-to-reach regions.
Sputnik V vaccine is approved by 70 countries with a total population of 4 billion people – over 50 % of the world population. The vaccine supplies for the global market will be produced by RDIF’s international partners in India, Brazil, China, South Korea and other countries.
After the Sputnik V vaccine’s clinical trial preliminary results showed its efficacy at above 90 percent, RDIF was the first to offer collaboration to other vaccine manufactures when on November 23, 2020 it suggested joint mix & match trials to AstraZeneca.
Now other producers are following in Sputnik V’s footsteps and trials have been ongoing around the world of the Russian vaccine with other vaccines (including in Azerbaijan, UAE and Argentina). These trials are confirming complete safety and high efficacy of this approach. The interest in mix and match approach is part of the RDIF’s global strategy aimed at boosting efficiency of other COVID-19 vaccines.
For more information visit www.sputnikvaccine.com and follow Sputnik V on social networks.